Written and maintained by CASRAI Editorial Board
Published
This page describes products and general use; it is not medical advice.
On this page
Short answer
The cobas Liat System is a compact, automated real-time polymerase chain reaction (PCR) platform manufactured by Roche Molecular Systems. Designed for near-patient and point-of-care (POC) clinical settings, it integrates sample purification, nucleic acid extraction, amplification, and real-time detection into a single-use flexible tube. It delivers definitive diagnostic results in approximately 20 minutes across respiratory, strep, and sexually transmitted infection assays.
Definition and scope
The cobas Liat (an acronym reflecting its underlying “Lab-in-a-tube” design) is an in vitro diagnostic (IVD) molecular testing platform. Classified by the U.S. Food and Drug Administration (FDA) as a Class II medical device under 21 CFR 862.2570 (Real Time Nucleic Acid Amplification System, Product Code OOI), the platform automates the complex multistep chemistry of nucleic acid amplification testing (NAAT) within a closed, self-contained disposable format.
Historically developed by IQuum, Inc. and acquired by Roche in 2014, the cobas Liat system bridges the gap between conventional central-laboratory PCR instruments and rapid lateral flow antigen immunoassays. Traditional clinical molecular diagnostics require dedicated extraction workstations, specialized thermocyclers, skilled molecular technologists, and cleanroom facilities to prevent amplicon contamination. In contrast, the cobas Liat analyzer packages all fluidic, thermal, and optical functions into an instrument weighing only 3.76 kg (8.3 lbs) with a benchtop footprint measuring 24.1 cm in depth, 11.4 cm in width, and 19.0 cm in height.
The operational scope of the cobas Liat system encompasses urgent care clinics, hospital emergency departments, pediatric clinics, physician office laboratories (POLs), decentralized satellite laboratories, and retail health facilities. Many of its flagship assays have received FDA 510(k) clearance alongside CLIA Categorization of Waiver, enabling facilities operating under a CLIA Certificate of Waiver to deliver laboratory-grade PCR results during an initial clinical encounter. Public regulatory filings indexed in openFDA medical device datasets demonstrate extensive clearance history across respiratory and infectious disease targets, validating its utility as a frontline diagnostic tool.
How it works or how it is used in practice
Understanding how the cobas Liat operates requires examining both the physical design of its disposable assay cartridge and the mechanical and optical systems inside the benchtop analyzer. The entire testing workflow is engineered to eliminate fluidic contact with the instrument hardware, completely avoiding internal tubing, fluidic manifolds, wash pumps, and waste reservoirs.
The “Lab-in-a-Tube” Cartridge Architecture
The cornerstone of the platform is the proprietary cobas Liat assay tube. This single-use, closed consumable is constructed from a flexible polymeric sleeve partitioned into multiple distinct segments by peelable internal physical barriers. Each segment comes pre-filled from the factory with precise micro-volumes of stabilized liquid or lyophilized biochemical reagents, including:
- Lysis reagents formulated to disrupt viral envelopes, capsids, and bacterial cell walls.
- Paramagnetic glass particles (magnetic beads) engineered to selectively bind liberated nucleic acids (DNA and RNA) in the presence of chaotropic salts.
- Sequential wash buffers that effectively remove cellular debris, proteins, lipids, and endogenous enzymatic inhibitors (such as hemoglobin, mucin, or bile salts).
- Elution buffers and reconstituted real-time PCR master mix containing heat-stable polymerases, reverse transcriptase (for RNA targets), deoxynucleotide triphosphates (dNTPs), target-specific primers, and dual-labeled fluorogenic hydrolysis probes.
Mechanical Actuator Array and Fluidic Manipulation
When an operator inserts a loaded assay tube into the analyzer and closes the motorized door, a series of micro-controlled mechanical actuators (functioning as precision plungers and clamps) engage with the exterior of the tube. These actuators compress and release specific segments of the flexible tube in a computer-timed sequence. By pinching down across internal barrier seals, the actuators rupture the peelable membranes, allowing fluids to move sequentially between compartments.
Because pressure is applied entirely from the exterior, the actuators function as integrated peristaltic pumps and micro-valves. An external magnetic mechanism draws the paramagnetic particles against the inner wall of the tube segment while actuators express the wash buffers past the captured nucleic acids. This automated protocol provides comprehensive inhibitor removal and target nucleic acid purification without requiring a micro-centrifuge or robotic liquid handling arms.
Thermal Cycling and Optical Detection
Once extraction and purification are complete, the purified nucleic acid and master mix are pushed into the reaction chamber at the base of the tube. Here, rapid thermal cycling takes place. Unlike bulky block cyclers, the miniaturized reaction zone allows rapid heating and cooling transitions via thermoelectric Peltier elements and precision resistive heaters, achieving heating and cooling rates of several degrees Celsius per second.
During the extension phase of each PCR cycle, multi-channel optical fluorometers illuminate the reaction chamber. As the polymerase cleaves the target-specific fluorogenic hydrolysis probes, fluorescent signals are captured across distinct wavelengths (such as FAM, HEX/VIC, and Cy5 channels). An onboard microprocessor monitors fluorescence amplification curves in real time, applies baseline correction, evaluates internal control thresholds, and generates an automated qualitative result (“Detected”, “Not Detected”, or “Invalid”) within approximately 20 minutes.
Clinical Workflow in Daily Practice
In routine clinical practice, operating the cobas Liat requires minimal hands-on preparation. The standard operational sequence follows these validated steps:
- Cartridge Barcode Scan: The operator powers on the analyzer, logs in using a dedicated user ID or operator barcode, and selects “Run Assay”. The instrument’s onboard optical scanner reads the 2D data-matrix barcode on the assay tube sleeve, registering the assay type, lot number, and expiration date.
- Sample Addition: The operator adds the specified volume of patient specimen (e.g., universal transport medium from a nasopharyngeal swab, liquid Amies, or urine transport buffer) into the opening of the cobas Liat tube using the transfer pipette provided in the kit.
- Sealing and Insertion: The tube cap is snapped shut to create a permanent, hermetic seal. The operator scans the patient ID barcode, inserts the sealed tube into the analyzer sleeve, and confirms the run.
- Automated Execution: The analyzer automatically locks the compartment, executes the thermal and fluidic protocol, monitors fluorometric signals, and displays the qualitative results on the touchscreen. Test records can be printed directly via an attached thermal printer or transmitted automatically to the facility’s Laboratory Information System (LIS) or Electronic Health Record (EHR) through an Ethernet interface.
Types or related concepts
The cobas Liat platform accommodates a comprehensive menu of qualitative molecular assays. While sharing the identical analyzer hardware, each assay cartridge features target-specific primer-probe sets, enzymatic formulations, and regulatory clearances. The table below outlines the primary assays cleared and commercialized on the cobas Liat system, referenced directly against U.S. FDA 510(k) clearances and product regulations.
| Assay Commercial Name | FDA Clearance / Identifier | 21 CFR Classification | FDA Product Code | CLIA Complexity | Clinical Targets | Specimen Matrix |
|---|---|---|---|---|---|---|
| cobas Liat Influenza A/B and RSV | K153544 / K210234 | 21 CFR 866.3980 | OCC | CLIA-Waived | Influenza A, Influenza B, Respiratory Syncytial Virus | Nasopharyngeal swab in viral transport media |
| cobas Liat Strep A | K141338 | 21 CFR 866.2680 | PGX | CLIA-Waived | Streptococcus pyogenes (Group A Strep) | Throat swab in liquid transport media or saline |
| cobas Liat SARS-CoV-2 and Influenza A/B v2 | K243400 | 21 CFR 866.3981 | QOF | CLIA-Waived | SARS-CoV-2, Influenza A, Influenza B | Naso/nasopharyngeal swab in viral media |
| cobas Liat SARS-CoV-2, Influenza A/B and RSV | K243406 | 21 CFR 866.3981 | QOF | CLIA-Waived | SARS-CoV-2, Influenza A, Influenza B, RSV | Nasopharyngeal swab in transport medium |
| cobas Liat Bordetella panel | K243753 | 21 CFR 866.3980 | OZZ | CLIA-Waived | Bordetella pertussis, Bordetella parapertussis | Nasopharyngeal swab specimens |
| cobas Liat CT/NG | K253756 | 21 CFR 866.3393 | QEP | CLIA-Waived | Chlamydia trachomatis, Neisseria gonorrhoeae | Vaginal swabs, female and male urine |
| cobas Liat CT/NG/MG | K253759 | 21 CFR 866.3393 | QEP | CLIA-Waived | C. trachomatis, N. gonorrhoeae, M. genitalium | Vaginal swabs, urine specimens |
| cobas Liat Cdiff | K171770 / K212427 | 21 CFR 866.3130 | OZN | Moderate Complexity | Toxigenic Clostridioides difficile (tcdB gene) | Unformed human liquid or soft stool |
A key operational distinction highlighted in the table is regulatory complexity. While the vast majority of respiratory and STI cartridges hold a CLIA-waived test categorization, the cobas Liat Cdiff test is classified by the FDA as Moderate Complexity. Consequently, healthcare settings operating exclusively under a CLIA Certificate of Waiver cannot legally run the Cdiff assay without upgrading their laboratory certificate and establishing full clinical personnel competency, proficiency testing, and validation programs under Good Laboratory Practice (GLP) standards.
Where it matters for labs, clinics or supply decisions
Point-of-care molecular testing represents a major logistical and economic decision for healthcare networks, diagnostic labs, and procurement teams. To understand where the cobas Liat system fits within institutional operations, facilities must contrast its operational profile against alternative testing modalities, such as rapid lateral flow antigen tests and high-throughput core-laboratory batch analyzers.
Diagnostic Modality Comparison
The table below provides a structured comparison across diagnostic modalities commonly employed in hospital and outpatient networks.
| Operational Dimension | cobas Liat System (POC PCR) | Lateral Flow Rapid Antigen (LFIA) | Central Laboratory PCR (e.g., cobas 6800/8800) |
|---|---|---|---|
| Diagnostic Technology | Automated real-time RT-PCR / PCR | Visual or fluorescent immunoassay | Automated high-throughput RT-PCR |
| Analytical Sensitivity | Very High (LOD ~10 to 100 copies/mL) | Moderate to Low (requires high viral load) | Very High (gold standard reference) |
| Turnaround Time (TAT) | ~20 minutes per sample | 10 to 15 minutes | 3 to 5 hours (excluding courier transport) |
| Throughput Architecture | Single-sample discrete random access | Parallel manual testing batches | Massive batched runs (384 to 1,000+ tests/shift) |
| Operator Skill Level | Minimal hands-on training (CLIA-waived) | Minimal training (CLIA-waived) | Specialized molecular medical laboratory technologists |
| Contamination Containment | Closed tube system; no exposed amplicons | Closed strip or cassette format | Segregated cleanroom zones and automated decontaminators |
| Clinical Workflow Impact | Immediate test-to-treat decision in clinic | Rapid triage; false negatives require PCR reflex | Retrospective or next-day patient management |
| Capital and Unit Cost | Moderate analyzer cost; higher per-test cartridge cost | Negligible instrument cost; lowest test cost | High capital investment ($200k+); lowest cost per test at scale |
Clinical and Economic Impact in Acute Care
The primary clinical value proposition of the cobas Liat lies in its ability to support definitive “test-to-treat” clinical decision-making during a single patient encounter. In emergency departments and urgent care centers, differentiating influenza from RSV or COVID-19 within 20 minutes dramatically alters management pathways:
- Antiviral Stewardship: Prescriptions for targeted neuraminidase inhibitors (e.g., oseltamivir) or cap-dependent endonuclease inhibitors (e.g., baloxavir marboxil) must be initiated within 48 hours of symptom onset to maximize therapeutic efficacy. Real-time PCR eliminates empirical prescribing and avoids unnecessary antibiotic usage for viral upper respiratory tract infections.
- Infection Prevention and Cohorting: In pediatric and adult emergency departments, rapid determination of RSV or Influenza status prevents nosocomial outbreaks by enabling immediate bed placement, private room assignment, or cohort isolation. Multicenter clinical evaluations in acute care settings (such as studies published in the Journal of Clinical Microbiology, PMC13463847) demonstrate that point-of-care PCR multiplexing significantly decreases patient boarding time and eliminates confirmatory reflex testing costs.
- Sexual Health and Patient Compliance: Sexually transmitted infection testing for Chlamydia trachomatis, Neisseria gonorrhoeae, and Mycoplasma genitalium traditionally suffers from significant patient loss to follow-up when central lab turnaround takes 48 to 72 hours. The availability of 20-minute, CLIA-waived STI multiplexing allows clinicians to prescribe pathogen-directed therapy prior to patient discharge, directly interrupting transmission chains. Large-scale multicenter clinical evaluations across 13 diverse U.S. POC sites (PMC12710341) confirmed high diagnostic concordance between the cobas Liat and composite laboratory reference standards.
Laboratory Procurement and Facility Considerations
When evaluating the procurement of cobas Liat units, laboratory directors and supply chain managers must evaluate several technical and environmental parameters:
- Throughput Capacity Planning: Because each analyzer module processes exactly one cartridge at a time (~20 minutes per test), a single instrument achieves a maximum theoretical throughput of 3 tests per hour. Facilities experiencing high peak volumes during respiratory illness surges often deploy clustered banks of 3 to 6 analyzers connected to a single barcode reader and LIS hub to balance random-access flexibility with volume demand. Similar multi-device deployment strategies are commonly seen with other clinical instruments, such as the i-STAT point-of-care system.
- Environmental and Electrical Tolerances: The cobas Liat operates within an ambient temperature range of 15°C to 32°C (59°F to 89°F) and relative humidity between 15% and 80% (non-condensing), at elevations up to 2,000 meters above sea level. Power consumption is modest at 130 W (100–240 VAC, 50–60 Hz), making it compatible with standard clinical wall power circuits and uninterruptible power supply (UPS) backups.
- Reagent Storage and Cold Chain: Cartridges must be stored according to manufacturer package inserts (typically refrigerated at 2°C to 8°C until ready for use, with defined room temperature stability allowances prior to testing). Maintaining monitored cold storage in outpatient clinics is essential for preserving enzyme integrity.
- Quality Control (QC) Protocols: Under CLIA regulations, waived testing facilities must run external positive and negative liquid controls according to manufacturer package inserts, state guidelines, and whenever a new cartridge shipment or lot number is introduced. Detailed documentation in the facility’s QC ledger is required during regulatory inspections.
Common misunderstandings
Several misconceptions surround the cobas Liat platform, often arising from confusion between different diagnostic technologies or misinterpreting regulatory classifications:
- Misunderstanding 1: All cobas Liat assays are CLIA-waived.
Reality: While respiratory tests (Flu A/B, RSV, SARS-CoV-2), Strep A, and STI panels are CLIA-waived, the cobas Liat Cdiff assay is cleared as Moderate Complexity under 21 CFR 866.3130. Facilities with only a Certificate of Waiver cannot run Cdiff testing without violating federal laboratory regulations. - Misunderstanding 2: The analyzer uses internal fluidic pumps and lines that require routine fluidic decontamination.
Reality: The cobas Liat analyzer contains zero internal fluidic plumbing. The entire biochemical reaction, including lysis, bead washing, amplification, and optical detection, occurs within the hermetically sealed, flexible plastic tube. The mechanical actuators simply press against the exterior of the tube. Routine maintenance is limited to exterior surface cleaning and dust removal; no internal bleach flushes or decontamination washes are required unless an external cartridge leak occurs. - Misunderstanding 3: POC PCR has lower analytical sensitivity than central laboratory PCR.
Reality: Independent multicenter validation studies published in clinical microbiology literature demonstrate that the cobas Liat achieves analytical limits of detection and clinical diagnostic sensitivity (often 98% to 100%) virtually identical to central laboratory automated platforms like the Roche cobas 6800 or Panther Fusion. The automated magnetic bead extraction within the tube yields pure nucleic acid templates, avoiding the lower sensitivity characteristic of rapid antigen tests. - Misunderstanding 4: The analyzer can be used for batched high-throughput screening during major epidemic surges.
Reality: The cobas Liat is fundamentally a single-cartridge, discrete random-access instrument. It cannot process 96-well plates or batched tube racks. Attempting to use a single Liat analyzer for high-volume population screening will create severe specimen bottlenecks. High-volume testing demands dedicated core-laboratory batch platforms. - Misunderstanding 5: Operators must perform complex manual micropipetting of enzymes and buffers.
Reality: All buffers, magnetic beads, enzymes, and primers are pre-packaged and sealed inside the tube segments during manufacturing. The clinical operator only performs a single liquid transfer: introducing patient sample into the top tube segment using the fixed-volume transfer pipette provided in the kit.
Frequently asked questions
What is the turnaround time for a cobas Liat test?
The cobas Liat analyzer delivers qualitative diagnostic results in approximately 20 minutes from the time the cartridge is inserted and the door is closed. Time to result can range from 15 to 20 minutes depending on the specific cycling protocol of the assay (e.g., Strep A vs. multiplex respiratory panels).
Can the cobas Liat be operated in a CLIA-waived clinical setting?
Yes. The cobas Liat instrument and most of its commercial assay menu (including cobas Strep A, cobas Influenza A/B and RSV, cobas SARS-CoV-2 and Influenza A/B, and cobas Liat CT/NG) have received FDA 510(k) clearances with CLIA Categorization of Waiver. They can be performed in any clinical setting holding a valid CLIA Certificate of Waiver, provided operators follow the manufacturer’s quick reference guide and instructions for use.
How does the cobas Liat prevent amplicon contamination in point-of-care environments?
The cobas Liat prevents post-amplification environmental contamination through its sealed, closed-tube design. Once the patient specimen is loaded and the tube cap is closed, the cartridge remains permanently sealed. All physical transfers, cell lysis, magnetic particle separation, and thermal cycling occur inside the tube via external actuator compression. At no point are amplicons exposed to the clinic environment.
What physical and electrical space is required for the analyzer?
The analyzer is designed for compact benchtop use, measuring 24.1 cm (9.5 inches) in depth, 11.4 cm (4.5 inches) in width, and 19.0 cm (7.5 inches) in height. It weighs 3.76 kg (8.3 lbs) and operates on standard electrical supplies of 100–240 VAC (50–60 Hz) with a maximum power draw of 130 W.
What happens if a run fails or yields an “Invalid” result?
If the analyzer encounters an optical error, hardware anomaly, or fails to detect the internal process control (indicating severe sample inhibition or extraction failure), the run is flagged as “Invalid”. The sample cannot be re-run in the same tube because reagents are depleted. The operator must prepare a fresh cartridge using leftover patient specimen or collect a new swab, following the troubleshooting guidelines outlined in the product documentation.
Does the cobas Liat require daily calibration?
No daily optical calibration is required by the operator. The instrument performs internal self-tests during power-up and monitors internal controls with every run. External liquid quality control (QC) materials must be run periodically in accordance with the manufacturer package insert, institutional standard operating procedures, and state or federal laboratory accreditation requirements.
Sources
- U.S. Food and Drug Administration. Premarket Notification 510(k) Database: cobas Influenza A/B and RSV Nucleic Acid Test for Use on the cobas Liat System (K153544) and cobas Liat Analyzer (K111387). Silver Spring, MD: U.S. FDA. Accessed November 12, 2026. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm
- U.S. Food and Drug Administration. Product Classification Database: Real Time Nucleic Acid Amplification System (21 CFR 862.2570, Product Code OOI) and Respiratory Virus Panel (21 CFR 866.3980, Product Code OCC). Silver Spring, MD: U.S. FDA. Accessed November 12, 2026. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/classification.cfm
- U.S. Food and Drug Administration. AccessGUDID Database: cobas Liat Analyzer (Model 07341920190, Primary DI 07613336100097, GMDN 48031). Silver Spring, MD: U.S. FDA / NLM. Accessed November 12, 2026. https://accessgudid.nlm.nih.gov/
- Roche Molecular Systems, Inc. cobas Liat System User Guide, Specifications and Assay Instructions for Use (IFU). Pleasanton, CA: Roche Diagnostics. Accessed November 12, 2026. https://diagnostics.roche.com/
- Rautava, M., et al. “From triplex to tetraplex: evaluation of the diagnostic accuracy of the new Roche Cobas Liat SARS-CoV-2, influenza A/B and RSV assay.” Journal of Clinical Microbiology, PMC13463847 (2026). Accessed November 12, 2026. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13463847/
- Van Der Pol, B., et al. “Sensitivity and specificity of the Cobas Liat CT/NG/MG nucleic acid test in a clinical laboratory setting and point-of-care location.” Journal of Clinical Microbiology, PMC12710341 (2025). Accessed November 12, 2026. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12710341/







